Which of the three weapons is better in the fight against Ozempic-Mounjaro or Wegovy obesity? Know which medicine produces the best results

To control obesity and diabetes worldwide, many companies have developed GLP-1 and semaglutide medicine that controlled diabetes and helped people overweight to lose weight. Monzaro and Vagovi have been officially launched in India, but it is now reported that the Central Drug Standards Control Organization (CDSCO) Novo Nordisk’s Blockbuster Medicine, Ozmpic (semaglutide injection) approved for use in India. This approval, which is valid until September 26, 2025, allows the use of Ozmpic with diet and exercise for type 2 diabetes. What are Ozmpic, Monjaro and Vegovi? Over the years, medicine for obesity and diabetes control has emerged, which is available in the form of injections and is given once a week. Currently, only Monjaro and Vegovi are available in India, and Ozmpic, which has been approved, will also be available soon. The Ozmpic and Vegovi are produced by Novo Nordisk, while Monzaro is formed by Eli Lily. The most important ingredient in Ozmpic and Vegovi is semaglutide, while Monzaro contains tirzepatide. Ozmpic and Monjaro were originally developed for handling type 2 diabetes, but the Vegovi received the approval of FDA, specifically for weight loss. How Ozmpic, Monjarso and Vegovi mimic hormones that control hunger and sugars in the body. Ozmpic and Vegovi are GLP-1 receptor agonists, which helps you keep the stomach empty and keep you for a long time. It reduces appetite and helps control blood sugar. On the other hand, Monzaro acts as a double GIP and GLP-1 receptor agonist, which not only reduces appetite but also increases fat burning and weight loss. Clinical trials have shown that Ozmpic and Vegovi could lose an average of 10-15%, while Monjaro could lose about 20%. Ozmpic, Monjaro and Vagovi in ​​India have been approved in India, so the company has not yet confirmed the right price of this drug. Monzaro is available in India in doses of 2.5 mg and 5 mg. The price of 2.5 mg of medicine is £ 3.500 and 5 mg scale is £ 4,375. This medicine is given once a week. The monthly cost of 2.5 mg (4 weeks) is £ 14,000, and the monthly cost of 5 mg is approximately £ 1700. Wagovi was introduced in five doses in India: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. The dose of 0.25 mg, 0.5 mg and 1 mg was priced £ 4,366. The 1.7 mg dose is priced at £ 6,070 and the 2.4 mg dose is £ 6,503. Benefits and losses The greatest benefit of Ozmpic, Monkero and Vegovi is that it helps to control diabetes. This medicine can also help with weight loss. Some medicines also showed positive effects on heart health and lifestyle diseases. The company claims that Ozmpic can also be beneficial to heart and kidneys. However, Ozmpic has not been approved to treat obesity. Along with its benefits, there are some disadvantages of these medicines listed on their official websites. Common side effects include nausea, vomiting, constipation, abdominal pain and fatigue. The use of long term is also linked to the risk of thyroid crops (seen in animals), pancreatitis and gallbladder problems.